Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.

Abstract: The present invention relates to a process for preparing immunogenic compositions. More particularly, it relates to a process for preparing liquid compositions of Protein D polypeptide and their use in preparing immunogenic compositions comprising Protein D polypeptide which may be used in the treatment or prevention of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a subject, e.g. human.

Abstract: The present invention relates to a process for preparing immunogenic compositions. More particularly, it relates to a process for preparing liquid compositions of Protein D polypeptide and their use in preparing immunogenic compositions comprising Protein D polypeptide which may be used in the treatment or prevention of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a subject, e.g. human.

Abstract: The present invention relates broadly to microfluidic devices, particularly microfluidic devices optimised for the industrial production of nanoparticles such as liposomes. The device (101) comprises a substrate which extends between a distal end (107) comprising an outlet region (105) and a proximal end (108) comprising an inlet region (106). The inlet region comprises two substantially parallel outer channels (103a, 103b) for transport of a first fluid, said outer channels (103a, 103b) defined in part by a first outer wall (109a) and a second outer wall (109b) respectively, and a linear inner channel (104) for transport of a second fluid. The linear channel is disposed between the two substantially parallel outer channels. The outer channels (103a, 103b) and inner channel (104) extend from the proximal end (108) to a mixing chamber (102) which extends from the inlet region (106) to the outlet region (105).

Abstract: Nanoparticles encapsulating polysaccharide conjugates and compositions comprising same are provided. Particularly the nanoparticles are prepared using a microfluidic device.

Abstract: Methods for manufacturing a non-viral delivery system comprising a liposome encapsulating an RNA using a microfluidic device and compositions for use therein are provided.

Abstract: The present invention concerns drug delivery particles which can prevent interaction between a biologically-active cargo comprised within the particles and components of an aqueous environment in which said particles are present. The particles are sensitive to pH such that above a threshold pH level the biologically-active cargo becomes accessible to the surrounding environment. Such particles are accordingly useful for stably storing a biologically-active cargo in an aqueous composition containing components which would otherwise interact deleteriously with the cargo, and releasing the cargo to mediate a biological effect in the body of an animal, such as a human, to which the composition is administered. Also provided are compositions comprising such particles, as well as methods for making and using such particles and compositions.

Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.